Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A longitudinal study to investigate innate immune reprogramming following Herpes Zoster vaccinati... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'Phase I/II study of Mezigdomide and Elranatamab for relapsed/refractory multiple myeloma patients... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'Phase Ib/II Study of Tislelizumab in Combination with Bevacizumab and Capecitabine in Advanced So... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose S... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Ph... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 randomized, double-blind, placebo-controlled, single-ascending-dose study investigating... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Pl... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A multicenter, randomized, double-blind, placebo-controlled Phase 2 study to investigate the effi... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solu... Read More
Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib ... Read More